Regulatory News:
DiaGenic ASA (OSE:DIAG) is invited to present at DNB Markets Nordic Health Care Conference 2011. DiaGenic CEO Erik Christensen will hold the presentation on Tuesday 6 December at 9:30 local time.
The presentation describes DiaGenic's latest scientific innovations put into a business context. The presentation also gives an indication of the US market potential for diagnostic use based on recent market surveys.
The presentation material will be available at the Company's website: www.diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer's Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com
This information was brought to you by Cision http://www.cisionwire.com
Contacts:
Erik Christensen, CEO
Telephone: 47 95939918
e-mail: erik.christensen@diagenic.com
